Brief: Tarsus Pharmaceuticals Q3 Basic EPS USD -0.61
13/11/2024 21:05
Nov 13 (Reuters) - Tarsus Pharmaceuticals Q3 net income USD -23.42 million vs. IBES estimate USD -34.8 million. * Q3 operating expenses USD 73.28 million
Recent news on Tarsus Pharmaceuticals
See all newsBrief: Lisata Therapeutics Appoints Jeff Farrow To Board Of Directors
Brief: Tarsus Pharmaceuticals Files For Offering Of Up To 2.91 Million Shares Of Common Stock By Selling Stockholders
U.S. RESEARCH ROUNDUP-Argan, Mastec, Oracle
Tarsus Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition (updated)